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total of 84 active ingredients had new indications or label changes. After removal of 
25 duplicate ingredients (or updated again during this timeframe), 59 labels and IFs 
were identified and reviewed. No product labels contained PRO information. However, 
in contrast 20 (34%) IFs contained PRO information. 10 of these IFs only stated that 
“QOL” or “PRO” was assessed without details on the questionnaires or results. The 
EORTC (European Organisation for Research and Treatment of Cancer) and FACT 
(Functional Assessment of Cancer Therapy) were explicitly stated as measures in 
four and three IFs, respectively. There were also three pain assessments; two Visual 
Analog Scale assessments and one utilizing the Brief Pain Inventory – Short Form 
(BPI-SF). ConClusions: Although no oncology labels contained PRO information, 
the IFs contained PRO information. 1/3 of product information contained a mention 
of PROs which can be used in discussions with clinicians.
PCN165
ChaNges iN PatieNt-RePoRted outComes amoNg PediatRiC Leukemia 
aNd LymPhoma PatieNts duRiNg the FiRst 2-yeaRs Post aLLogeNeiC 
stem CeLL tRaNsPLaNtatioN (aLLosCt)
Oberg J.A.1, Morris E.2, Cairo M.2, Kelly K.M.1
1Columbia University, New York, NY, USA, 2New York Medical College, Valhalla, NY, USA
objeCtives: To explore changes in child-reported quality of life (QOL) of pediatric 
leukemia/lymphoma patients receiving alloSCT. Methods: Hierarchical linear 
modeling was used to explore trends in select PedsQL 4.0 sub-scales and individual 
items of 43 children ≥ 5 years of age. QOL was assessed once pre-alloSCT and on 
days 100, 180, 365, and 730, post-alloSCT. Results: Median age: 13.54 years, Range: 
4.66-23.12 years; leukemia: 76.7%; lymphoma: 23.3%; reduced-toxicity conditioning 
(RTC)/myeloablative conditioning (MAC): 44%/56%; chronic graft-versus-host disease 
(cGVHD): 27.9%. Emotional and social functioning was stable pre-to-post-alloSCT 
and comparable to a normative pediatric sample (p> .05), whereas physical func-
tioning was 19 points lower pre-alloSCT (M= 67.42; p< .01; ES= 1.26SD) with improved 
scores approaching norms by Day +730. 51-65% of children at baseline reported dif-
ficulties with sports/exercise, strength, pain, and fatigue. Significant improvements 
from baseline (M= 51.41) were observed in sports/exercise at a rate of 1.06 points-
per-month (ppm)/12.90 points-per-year (ppy) (t= 2.57; p= .01) and strength (M= 47.47; 
t= 2.05; p= .04) at a rate of 0.84 ppm (10.21ppy). Recipients of RTC significantly 
improved at a rate of 14.04ppy (slope= 1.16; t= 2.41; p= .02) compared to children who 
received MAC (-4.01ppy; slope= -0.33). Similarly gains in strength were significantly 
better for the RTC group (12.94ppy; slope= 1.06; t= 2.25; p= .02) than the MAC group 
(-10.62ppy; slope= -0.83). Levels of pain (M= 64.82; slope= 0.05ppm; t= 0.15; p= .88) and 
fatigue (M= 58.01; slope= 0.39ppm; t= 1.14; p= .26) remained unchanged irrespective 
of conditioning regimen. Emotional functioning of children ages 8-12 significantly 
improved from baseline (M= 70.18; slope= 1.78ppm; t= 2.89; p= .01), whereas children 
≥ 13 significantly declined post-alloSCT (M= 72.61; slope= -1.34ppm; t= -2.64; p= .01). 
Presence of cGVHD did not significantly affect outcomes scores. ConClusions: 
Improvements in exercise and strength were seen with RTC regimens whereas 
pain and fatigue remained unchanged independent of conditioning regimen. Older 
children may have more emotional difficulties post-alloSCT. These results highlight 
the importance of including QOL to monitor patients and further define outcomes 
for this population.
PCN166
QuaLity oF LiFe iN PatieNts with ostomy iN PoLaNd: muLtiCeNtRe 
CRoss-seCtioNaL study usiNg whoQoL-BReF QuestioNNaiRe
Golicki D.1, Styczen P.2, Szczepkowski M.3
1Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, 
Poland, 2Gabinet Lekarski, Konopiska, Poland, 3Faculty of Rehabilitation, Jozef Pilsudski University 
of Physical Education in Warsaw, Warsaw, Poland
objeCtives: To assess quality of life of Polish patients with a stoma using validated 
generic questionnaire. Methods: Adult patients with colostomy, ileostomy or uro-
stomy performed in Poland between July 2009 and December 2010 were included. 
Patients completed satisfaction survey at the discharge from the hospital, and The 
World Health Organization Quality of Life-BREF (WHOQOL-BREF) generic question-
naire at 3 months after surgery. Results: The study involved 1519 patients (71.5%, 
16.8%, 11.7% with colostomy, ileostomy and urostomy, respectively). The studied 
population was highly diversified in terms of: pain and discomfort, dependence on 
medical treatment and acceptance of physical appearance. 57% of patients with a 
stoma defined their quality of life as good or very good (mean 3.54 points; range: 
1 to 5; SD 0.73). The subjects were characterized by low quality of life assessment 
in the physical health and psychological domains (53.5 and 60.0 pts.) and by high 
evaluation in the environment and social relationships domains (69.6 and 70.2 pts.). 
Respondents highly assessed: the level of social support, home environment, physi-
cal environment, personal relationships. Low assessment was related to: sexual 
activity, ability to work, dependence on medical treatment, financial resources, 
satisfaction with health. ConClusions: This is the first Polish study on the quality 
of life of patients with a stoma, based on validated generic questionnaire. The results 
should help improve standards of care for patients with a stoma.
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iNFLueNCe oF aNxiety aNd dePRessioN oN 1-yeaR heaLth ReLated 
QuaLity oF LiFe iN CoLoReCtaL CaNCeR PatieNts
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objeCtives: To assess the impact of anxiety and depression measured by Hospital 
Anxiety and Depression Scale (HADS) on 1-year HRQoL measured by EuroQol-3L (EQ-
5D) and EORTC-QLQ-C30 on patients with colorectal cancer.This aspect of continuity 
tions, year, PRO instrument, and results for PROs. Analysis was conducted to identify 
trends in commonly used PRO instruments and results were categorized as posi-
tive, neutral, or negative. Results: Eight RCTs with a total of 3,342 patients were 
identified. In these studies, there were eight different PROs instruments identified: 
FACT-Leu, SF-36, FSI, PSQI, MSAS-SF, FACT-BRM, EQ-5D, and MDASI-CML. The most 
commonly used instruments were FACT-Leu (used in 1,336 patients) and FACT-BRM 
(used in 1,199 patients). Five studies reported positive results with improvement in 
quality of life (QoL) symptoms versus comparator treatments. Two studies reported 
results highlighting significant deterioration in QoL versus patients with no cancer. 
One study reported QoL in various types of CML and showed significant deterioration 
in patients with chronic phase CML versus those with acute and blast phase CML. 
Studies also identified two QoL domains, depression and fatigue, which matter most 
for patients with CML. ConClusions: Patients with CML have significant deterio-
ration in their QoL. PRO instruments such as FACT-Leu and FACT-BRM can aid in 
generating evidence to show which therapies improve patient QoL.
PCN162
PatieNt RePoRted outComes iN metastatiC CastRatioN-ResistaNt 
PRostate CaNCeR
Aggarwal S., Segal J., Kumar S.
Novel Health Strategies, Bethesda, MD, USA
objeCtives: Patient reported outcomes (PRO) are becoming useful tools for col-
lecting and generating evidence for new medical products to show improvements 
in health-related quality of life (HRQoL). Castration-Resistant Prostate Cancer 
(CRPC) is a chronic disease with high importance for patient HRQoL. The objective 
of this study was to review, analyze, and understand trends in the PRO instruments 
used in patients with CRPC. Methods: A systematic literature search for CRPC 
randomized controlled trials (RCTs) with PROs endpoints was undertaken for the 
databases Pubmed, Embase, Biosis, Google Scholar, and Cochrane. Data was col-
lected for the study size, interventions, year, PRO instrument, and results for PROs. 
Analysis was conducted to identify trends in commonly used PRO instruments 
and categorize results as positive, neutral or negative. Results: Ten RCTs with 
a total of 5,797 patients were identified. In these studies there were thirteen dif-
ferent PROs instruments were identified that were FACT-P, FACT-G, BPI-SF, EQC30, 
EQPR25, FLIC, SDS, SUF, PDA, IPDA, PROSQOLI, SF-36, and QOLM-P14. The most 
commonly used instrument were FACT-P (used in 4,297 patients) and EQC-30 (used 
in 1,091 patients). Six studies reported positive results with improvement in qual-
ity of life symptoms (QoL) versus comparator treatments. Fours studies reported 
results with deterioration in (QOL). Three studies reported improvement in pain 
scores. ConClusions: Patients with CRPC have relatively longer survival and 
hence QoL is an important consideration for these patients. PRO instruments such 
as FACT-P and EQC-30 have been commonly used to generate evidence to show 
which therapies improve patient QoL.
PCN163
aRe “dizzy” aNd “Lightheaded” the same CoNCePt oR sePaRate 
CoNCePts? ChaLLeNges iN CoNCePtuaL eQuivaLeNCe oF these teRms iN 
20 LaNguages
Eremenco S.1, Arnold B.J.2
1Evidera, Bethesda, MD, USA, 2FACITtrans, Elmhurst, IL, USA
objeCtives: Feeling “dizzy” or “lightheaded” are common concepts in patient-reported 
outcome (PRO) instruments in a number of conditions. The Functional Assessment of 
Cancer Therapy – Anemia (FACT-An) subscale contains an item assessing “feeling dizzy 
(lightheaded)” as one concept while other instruments propose to assess the symptoms 
as two separate concepts or items. The purpose of this study was to translate and assess 
conceptual equivalence of this concept across 20 languages (21 countries). Methods: 
The FACT-An was translated following the FACIT Translation methodology which is 
consistent with ISPOR guidelines for translation and cultural adaptation of PRO 
measures (Wild et al., 2005). The translation process for each language consisted of: 2 
forward translations by native translators, reconciliation of the forward translations, 
1 back-translation by an English-speaker fluent in the target language, 3 reviews by 
native translators or clinicians, final reconciliation by a native speaking linguist, and 
harmonization. Interviews were conducted among 456 native-speaking patients in 21 
countries. Data were analyzed to assess linguistic and cultural validity of the FACT-An in 
each language and confirm conceptual equivalence. Results: Mean age of the sample 
(N= 456) was 55 years, (range 19-88) and 58% were male. During the translation phase, 12 
of the 20 languages translated the concept of dizzy (lightheaded) using only one term, 
and the remaining 8 languages provided two terms. The rationale was that one word 
was used to describe this set of symptoms and it would be a complicated explanation 
to address the second term. The translations were well understood and considered rel-
evant. ConClusions: The majority of languages in this study provided only one term 
for the concept of dizzy (lightheaded) indicating that it may be problematic to assess 
the concept as two separate symptoms in future questionnaires in other languages 
where this concept is not separated as it is in English.
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PRo CLaims iN JaPaNese oNCoLogy PRoduCt LaBeLiNg
Crawford B.
Adelphi Values, Tokyo, Japan
objeCtives: There is a growing use of patient-reported outcomes (PRO) in the US 
and Europe but little is known about Asia. Oncology in particular is an area of growing 
interest. This study sought to review PRO labeling within oncology products over the 
last five years in Japan. Methods: Oncology labels were identified by reviewing the 
Pharmaceutical and Medical Devices Agency (PMDA) postings of label changes for 
the past 5 years (2007-2012). For identified products with label changes, labels and 
Interview Forms (IF) were acquired and reviewed. The IF is used as a supplement to 
the label in Japan to provide additional data that will not fit within the package insert. 
Only PROs used for potential promotion were evaluated. Symptoms such as pain listed 
in the adverse events or safety sections were not included in this review. Results: A 
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aN exPLoRatoRy aNaLysis oF the assoCiatioN BetweeN eoRtC-QLQ 
C30 domaiNs aNd PRogRessioN FRee/oveRaLL suRvivaL iN advaNCed 
meLaNoma aFteR 12 weeks oF tReatmeNt oN iPiLimumaB ComPaRed to 
gP100 iN a Phase iii CLiNiCaL tRiaL
Lee D.1, Harvey B.1, Gaudin A.F.2, Gueron B.3, Bregman B.2, Lebbe C.4, Bonnetain F.5, Borget I.6
1BresMed, Sheffield, UK, 2Bristol-Myers-Squibb, Rueil Malmaison, France, 3Bristol-Myers Squibb, 
Rueil Malmaison, France, 4Hopital Saint Louis, Paris, France, 5CHU Besançon, Besançon, France, 
6Institut Gustave Roussy, Villejuif, France
objeCtives: This study analyses the association between health-related quality 
of life (HRQL) domains and progression free (PFS) and overall survival (OS) for ipili-
mumab, ipilimumab + gp100, and gp100 alone during the 12 week treatment induc-
tion period compared to baseline. The aim of this study was to assess whether 
outcomes reported in the EORTC-QLQ-C30 summary domains impact the hazard 
of progressing and/or dying after 12 weeks of treatment. Methods: Data from the 
MDX010-20 trial, including 676 previously treated patients with unresectable stage 
III or IV melanoma, was analysed. A domain correlation plot (excluding Global 
domain) was constructed to determine whether the EORTC-QLQ-C30 domains 
showed a high level of correlation for baseline scores. It was then used to derive 
two components summarising fourteen domain scores, Principal Components 
1, containing 10 domain scores (Pain, Appetite Loss, Nausea, Finance, Dyspnoea, 
Constipation, Diarrhoea, Role, Social and Physical) and 2 containing 4 domains 
scores (Fatigue, Sleep Disturbance, Emotional and Cognitive), based on the cor-
relation level between domains. These two Principal Components were entered as 
additional covariates in the Cox model for PFS/OS and hazard ratios were deter-
mined. Results: In the Cox regression model, Principal Component 1 showed a 
30% increase in hazard of progression when comparing the upper to the lower 
quartile of the Principal Component score , while a lower Principal Component 
1 score indicated a better HRQL at baseline. It was also showed a rate of death 
twice as high in the upper quartile than the lower quartile. Principal Component 
2 neither affected significantly PFS nor OS. ConClusions: In advanced mela-
noma treated by ipilimumab compared to gp100, PFS and OS were associated with 
most of the HRQL domain scores. These findings suggest that poor baseline HRQL 
could be predictive of poor PFS/OS, while higher baseline HRQL could predict a 
better outcome.
PCN171
QuaLity oF LiFe (QoL) duRiNg tReatmeNt oF NewLy diagNosed LoCaLLy 
CoNFiNed Low-Risk PRostate CaNCeR (LCLRPC) iN geRmaNy: ResuLts oF 
the haRow study
Schädlich P.K.1, Baranek T.2, Häussler B.1, Weißbach L.3
1IGES Institut GmbH, Berlin, Germany, 2CSG - Clinische Studien Gesellschaft mbH, Berlin, 
Germany, 3Stiftung Männergesundheit - Foundation for Men’s Health, Berlin, Germany
objeCtives: The optimal treatment choice for preserving QoL of the about 64,000 
men diagnosed with prostate cancer each year in Germany still remains unclear. The 
objectives therefore were to generate long-term information under day-to-day condi-
tions on QoL of men in Germany cared for newly diagnosed LCLRPC using hormonal 
therapy (HT), active surveillance (AS), radiotherapy (RT), operation (OP), or watch-
ful waiting (WW) – HAROW. Methods: The long-term observational multi-centre 
HAROW study was undertaken. The urologist provided all relevant clinical data of 
the patient. The patient provided inter alia data on QoL using the EQ-5D. Utilities 
derived from the EQ-5D based on the German value set were used to construct quality-
adjusted life-years (QALYs). QALYs were discounted by 3% annually and standardised 
to mean QALYs per patient-year (PY) for each initial treatment strategy. Differences 
between strategies were tested using the Kruskal-Wallis test (Bonferroni-corrected 
p= 0.0018 due to 28 tests). Results: Between July 2008 and March 2013, 3063 patients 
(mean age 67.3 ± 7.5 years) with LCLRPC (T1a–T2c, N0, M0) were included from 257 
urologists. Data on QoL were documented by patients as follows (% of patients/strat-
egy): AS n= 353 (78%), RT n= 291 (77%), HT n= 149 (71%), HT+RT n= 68 (85%), combination 
therapy (CT) n= 109 (80%), OP n= 1167 (71%), other therapy (OT) n= 9 (50%), WW n= 93 
(66%), over a mean time of between 1.6 (OT) and 2.5 years (CT). AS showed the highest 
undiscounted/discounted QALYs/PY (0.9297/0.9103) followed by OP (0.9289/0.9075), 
RT (0.9075/0.8878), CT (0.9071/0.8820), OT (0.8954/0.8818), HT+RT (0.8875/0.8699), WW 
(0.8646/0.8465), and HT (0.8485/0.8292). Compared to HT, QALYs/PY were significantly 
higher with AS (p< 0.0001), with OP (p< 0.0001), and with RT (p= 0.0002). Tests with 
undiscounted/discounted QALYs/PY adjusted for age, tumor stage and comorbidity 
showed no different results. ConClusions: According to the HAROW study, active 
surveillance yielded the highest QALYs of the different LCLRPC treatment strategies 
in Germany evaluated.
PCN172
hR-QoL data iN the amNog eaRLy BeNeFit assessmeNt: iNdustRy aNd 
iQwig/gBa PeRsPeCtive
Obradovic M., Radicek S., Rauland M.
GfK Bridgehead, Nuremberg, Germany
objeCtives: To explore how often and which types of quality of life (QOL) data are 
included in the dossiers submitted for the AMNOG early benefit assessment and 
analyze how a drug’s effect in QOL is interpreted by the industry and the evaluating 
committee. Methods: The published value dossiers up to June 15, 2013 and the cor-
responding benefit assessments were reviewed. Types of QOL data and the statements 
concerning QOL in the value dossier and the benefit assessments were collected and 
summarized. Results: A total of 46 cases were analyzed. In 6 cases no dossier was 
submitted. Of the rest, 13 dossiers (32.5%) did not include any QOL data, 13 (32.5%) 
included disease-specific QOL data only, 5 (12.5%) included generic QOL data only, 
and 9 (22.5%) both types. The QOL instruments used were considered as valid by the 
assessors. However, outcomes such as pain severity, fatigue, work productivity, and 
health care resource use were not regarded as QOL measures. Of 27 dossiers that have 
included QOL data companies have claimed an added benefit in QOL, either for the 
whole population or a specific subgroup, in 15 (56%) cases. However, the assessors rec-
of care could be nowadays a major issue Methods: This prospective study carried 
out in 12 Hospitals. At baseline patients fulfilled EQ-5D questionnaire (utility and 
VAS scale), EORTC-QLQ-C30 (physical, role, emotional, cognitive and social function-
ing, and global health) and HADS. One year post-surgical management they com-
pleted the EQ-5D and EORTC-QLQ-C30. We used general linear models to establish 
the influence of baseline anxiety (HADS-A) and depression (HADS-D) on changes in 
HRQoL, adjusted by baseline score and gender. We have used the recommended cut-
off points of HADS ≤ 7 (normal); 8-10 (uncertain) and ≥ 11 (problem). Results: There 
were 778 patients. The mean age (SD) was 67.4 (10.4). Males represented the 62.7%. 
At baseline, in the HADS-A there were 282 (36.4%) of patients scoring higher than 7 
points (17.6% higher than 10 points). In the HADS-D 137 (17.6%) scored higher than 7 
and 9.3% were higher than 10 points. Both anxiety and depression at baseline influ-
ence the changes in EQ-5D, with less gains in patients with more level of anxiety 
or depression (p< 0.0001). Regarding the EORTC-QLQ-C30 domains, baseline anxiety 
level impacts significantly in all domains, except in physical functioning, with gains 
around 5 to 11 points lower in patients with anxiety problems comparing with those 
classified as normal (all p< 0.05). Baseline depression level impacts significantly on 
changes in role and social functioning, and global health, with gains around 10 to 
13 points lower in patients with depression problems (all p< 0.01). ConClusions: 
This study supports the importance of providing psychological interventions for 
cancer patients before surgical management.
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a PRoPosed 6-item ReduCtioN FoR the euRoPeaN oRgaNizatioN FoR the 
ReseaRCh aNd tReatmeNt oF CaNCeR-QuaLity oF CoRe QuestioNNaiRe 
(eoRtC QLQ-C30) - CuBaN gRouP oF tRiaLists oN ePideRmaL gRowth 
FaCtoR (Cgt-egF)
Viada C.1, Ballesteros J.2, Fors M.3, Luaces P.1, Sánchez L.1, Crombet T.1
1Center of Molecular Immunology, Havana, Cuba, 2University of the Basque Country UPV/EHU, 
Leioa, Spain, 3National Coordinating Centre of Clinical Trials, Havana, Cuba
objeCtives: To develop an unidimensional and short version of the QLQ-C30 to be 
used as a patient-perceived quality of life in cancer trials. Methods: We analysed 
data of 873 patients diagnosed with non-small-cell lung cancer who participated 
in 4 Cuban multicenter trials of immunotherapy against the epidermal growth 
factor. The analysis followed a 4-step approach. First, we conducted a Mokken 
nonparametric item response analysis to ascertain the QLQ-C30 dimensionality 
and separate several scales if appropriate. Second, we conducted a parametric 
Samejima’s graded response model (GRM) to assess the item characteristics and 
information. Third, we did a confirmatory factor analysis (CFA) to test the scales 
unidimensionality and to obtain standardised factor loadings to suggest a reduced 
version of the QLQ. Finally, we assessed the discriminative validity of the reduced 
version by using receiver-operator curve (ROC) analysis. Results: Mokken analy-
sis of the QLQ-C30 resulted in a unidimensional scale, with an overall scalability 
of 0.43 that defined a medium scale. The unconstrained GRM showed that most 
items presented appropriate difficulty and discrimination parameters. The CFA 
supported an underlying unidimensional latent structure for the whole QLQ-C30 
(CFI = 0.98; RMSEA = 0.05) with modification indexes pointing to important redun-
dancy of information. The selection of items with standardized factor loadings 
> 0.70 lead to a 6-item QLQ that showed good discriminative validity against 
independent criteria of quality of life (ROC area = 0.76; 95% CI = 0.72 to 0.80) as 
compared with the values for the whole scale (ROC area = 0.70; 95% CI = 0.66 to 
0.74). ConClusions: The EORTC QLQ-C6 suggested in this study presents good 
psychometric properties and includes an unidimensional structure of patient-
perceived quality of life.
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evaLuatiNg the BuRdeN oF BoNe metastases (Bm) oN PatieNts with 
CastRatioN-ResistaNt PRostate CaNCeR (CRPC) aNd theiR tReatiNg 
PhysiCiaNs: FiNdiNgs FRom a RoutiNe PRaCtiCe study iN 13 medium-
sized euRoPeaN CouNtRies
Hechmati G.1, Vrouchou P.1, Arellano J.2, Cristino J.1, Haynes I.3, Liede A.4, Rider A.5,  
Worsfold A.5, Pollard R.5, Crossland V.5
1Amgen (Europe) GmbH, Zug, Switzerland, 2Amgen Inc., Thousand Oaks, CA, USA, 3Amgen Ltd., 
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objeCtives: To evaluate the burden of BM on patients with CRPC and their treat-
ing physicians. Methods: A total of 167 physicians (100 oncologists and 67 urolo-
gists) completed a prospective 5-day workload form, interview and average of 8 
patient record forms (PRFs, October 2012–March 2013) for non-metastatic and 
metastatic CRPC patients. Data from 142 workload forms, 167 interviews and 1,274 
PRFs (including 475 CRPC patients at ‘high risk’ of BM, 505 CRPC patients with BM 
only, 102 CRPC patients with BM and VM and 192 CRPC patients with VM only) 
were included in these analyses. Results: Physician interviews showed 92%, 
63% and 60% of the physicians believed the greatest patient burden of BM was 
back pain, reduced ability to perform daily activities and fractures, respectively 
(from a predetermined list where ‘other’ was specified). PRF data confirmed that 
Eastern Cooperative Oncology Group (ECOG) performance status was significantly 
worse in patients with BM (with/without VM) when compared with patients at 
high-risk of developing BM (p< 0.0001). 92% of the patients at ‘high-risk’ (defined by 
treating physician) of developing BM (n= 475) had a PSA doubling time (PSADT) ≤ 6 
months. The biggest burden of BM on treating physicians was seeing patient dete-
rioration (70% [n= 117]; 67% of oncologists; 75% of urologists), inability to propose 
effective treatment (57% [n= 95]; 60% of oncologists; 52% of urologists), managing 
complex regimens (29% [n= 49]; 27% of oncologists; 33% of urologists) and trans-
ferring patients for respite/hospice care (23% [n= 38]; 26% of oncologists; 18% of 
urologists). ConClusions: These data highlight the burden of BM on patients 
with CRPC and the perceived burden on physicians treating this population. BM 
are associated with a significant reduction in patients’ performance status and 
an increased burden on the patient. There is a need for treatments to prevent or 
delay the onset of BM and their associated burden.
